Characterization of molecular and structural determinants of selective estrogen receptor downregulators

Breast Cancer Research and Treatment

Volumn 103, Issue 1, 2007, Pages 37-44

  Fan, Meiyun ^a   Rickert, Emily L ^b   Chen, Lei ^a   Aftab, Syed A ^b   Nephew, Kenneth P ^a   Weatherman, Ross V ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Antiestrogen; Estrogen receptor degradation; GW5638; GW7604; Selective estrogen receptor downregulator; Selective estrogen receptor modulator; Tamoxifen

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GW 7604; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

BREAST NEOPLASMS; CELL PROLIFERATION; CINNAMATES; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; HUMANS; STILBENES; TUMOR CELLS, CULTURED;

EID: 34247536303     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9353-2     Document Type: Article

References (16)

1. Robertson JF (2004) Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 30:695-706
2. Osborne CK, Wakeling A, Nicholson RI (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(Suppl 1):S2-6
3. Normanno N, Di Maio M, De Maio E et al (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721-747
4. Willson TM, Norris JD, Wagner BL et al (1997) Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138:3901-3911
5. Wijayaratne AL, Nagel SC, Paige LA et al (1999) Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140:5828-5840
6. Fan M, Long X, Bailey JA et al (2002) The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol 16:315-330
7. Wu YL, Yang X, Ren Z et al (2005) Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18:413-424
8. Willson TM, Henke BR, Momtahen TM et al (1994) 3-[4-(1,2-Diphenylbut-1- enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 37:1550-1552
9. Weatherman RV, Clegg NJ, Scanlan TS (2001) Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chem Biol 8:427-436
10. Eaddy III, JF, Heyer D, Katamreddy SR et al (2005) Preparation of acyloxydiphenylbutenylcinnamates as estrogen receptor modulator prodrugs PCT application WO2005033056
11. Smyth TP, Corby BW (1998) Toward a clean alternative to Friedel-Crafts acylation: In situ formation, observation, and reaction of an acyl bis(trifluoroacetyl)phosphate and related structures. J Org Chem 63:8946-8951
12. Wijayaratne AL, McDonnell DP (2001) The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276:35684-35692
13. Robertson JF, Come SE, Jones SE et al (2005) Endocrine treatment options for advanced breast cancer-the role of fulvestrant. Eur J Cancer 41:346-356
14. Shao W, Brown M (2004) Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 6:39-52
15. Pike AC, Brzozowski AM, Walton J et al (2001) Structural insights into the mode of action of a pure antiestrogen. Structure (Camb) 9:145-153
16. Bohley P (1996) Surface hydrophobicity and intracellular degradation of proteins. Biol Chem 377:425-435